2023: Paxlovid Fully Approved

On This Day in Health: May 25, 2023

On May 25, 2023, the U.S. Food and Drug Administration approved Paxlovid for mild-to-moderate COVID-19 in adults at high risk of progression to severe disease, including hospitalization or death. The treatment had already been available under an emergency use authorization since December 2021. The new decision therefore marked a change in regulatory status rather than the medicine's first use during the pandemic. It became the first oral antiviral with full FDA approval for treating COVID-19 in adults. The original authorization and the later approval were separate milestones, each with its own evidence review and defined conditions of use.

Paxlovid combines nirmatrelvir with ritonavir. Nirmatrelvir inhibits a viral enzyme involved in producing functional proteins needed for replication. Ritonavir slows the breakdown of nirmatrelvir, helping maintain its exposure in the body. That combination also creates an important interaction problem, because ritonavir can affect the handling of other medicines. A prescription therefore requires review of the patient's medication list and health circumstances. The treatment is intended early in an illness for people whose risk justifies its use. It is not a preventive medicine taken before or after an exposure merely to stop infection from occurring, a distinction the FDA explicitly preserved in its announcement.

The approval drew primarily on the EPIC-HR randomized trial and the wider evidence submitted to the agency. EPIC-HR studied non-hospitalized adults with confirmed infection and risk factors for severe outcomes. The trial population and timing of treatment mattered when interpreting the reduction in hospitalization or death. A favorable group result did not mean that every treated person would have the same outcome or that all people with COVID-19 needed the medicine. The approved labeling carried a boxed warning about potentially serious drug interactions. The decision combined recognition of benefit for the indicated population with a clear expectation that prescribers would evaluate whether interaction risks could be managed.

May 25 captures the transition of a pandemic treatment from emergency authorization into the ordinary approval framework for a specified adult population. It also shows why the end of an emergency declaration does not automatically settle every question about medicines developed during that period. Patients still needed care, and regulators still had to distinguish access pathways, evidence and eligibility. The anniversary is meaningful when it makes those distinctions understandable. Paxlovid's full approval recognized a treatment option for high-risk adults while retaining the practical work of early assessment and safe prescribing. It was a step in the development of ongoing COVID care, rather than a declaration that the disease or its consequences had ended.